Folotyn (Pralatrexate Solution for Intravenous Injection) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Folotyn

Pancreatic Cancer »

Pancreatic cancer facts

Most pancreatic cancers are adenocarcinomas.
Few patients diagnosed with pancreatic cancer have identifiable risk factors.
Pancreatic cancer is highly lethal.
Pancreatic cancer is difficult to diagnose, and the diagnosis is often made late in the disease course. Symptoms include weight loss, back pain, and jaundice.
The only curable treatment is surgical removal of all cancer.
Chemotherapy after surgery can lower the chances of the cancer returning.
Chemotherapy for metastatic pancreatic cancer can extend life and improve the quality of life for people with the disease.
Patients diagnosed with pancreatic cancer are encouraged to seek out clinical trials to improve pancreatic cancer treatment.
Many organizations exist to help provide information and support for patients and families fighting pancreatic cancer.

Wh...

Read the Pancreatic Cancer article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Folotyn

Breast Cancer Slideshow Pictures

Pancreatic Cancer Slideshow Pictures

Skin Cancer Slideshow Pictures

font size

FOLOTYN
(pralatrexate) Injection

DRUG DESCRIPTION

FOLOTYN (pralatrexate injection) contains pralatrexate, which is an antineoplastic folate analog. Pralatrexate has the chemical name (2S)-2-[[4-[(1RS)-1-[(2, 4-diaminopteridin-6-yl)methyl]but-3ynyl]benzoyl]amino]pentanedioic acid. The structural formula is as follows:

FOLOTYN (pralatrexate) Structural Formula Illustration

Pralatrexate is a 1:1 racemic mixture of S- and R- diastereomers at the C10 position (indicated with *).

The molecular formula is C₂₃H₂₃N₇O₅ and the molecular weight is 477.48 g/mol.

Pralatrexate is an off-white to yellow solid. It is soluble in aqueous solutions at pH 6.5 or higher. Pralatrexate is practically insoluble in chloroform and ethanol. The pKa values are 3.25, 4.76, and 6.17.

FOLOTYN is supplied as a preservative-free, sterile, isotonic, non-pyrogenic clear yellow aqueous parenteral solution contained in a single-use clear glass vial (Type I) for intravenous administration. Each 1 mL of solution contains 20 mg of pralatrexate, sufficient sodium chloride to achieve an isotonic (280-300 mOsm) solution, and sufficient sodium hydroxide, and hydrochloric acid if needed, to adjust and maintain the pH at 7.5-8.5. FOLOTYN is supplied as either 20 mg (1 mL) or 40 mg (2 mL) single-use vials at a concentration of 20 mg/mL.

What are the precautions when taking pralatrexate solution for intravenous injection (Folotyn)?

Before using pralatrexate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease.

Do not have immunizations/vaccinations without the consent of your doctor. Avoid contact with people who have recently received live vaccines (such as flu vaccine inhaled through the nose).

To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like razors and nail cutters, and avoid activities such as contact sports.

Before having surgery, tell your...

Read All Potential Precautions of Folotyn »

Last reviewed on RxList: 3/2/2012
This monograph has been modified to include the generic and brand name in many instances.